Sackeim, Harold AAaronson, Scott TBunker, Mark TConway, Charles RDemitrack, Mark AGeorge, Mark SPrudic, JoanThase, Michael ERush, A John2022-04-132022-04-132019-060022-39561879-1379https://hdl.handle.net/10161/24812There is considerable diversity in how treatment-resistant depression (TRD) is defined. However, every definition incorporates the concept that patients with TRD have not benefited sufficiently from one or more adequate trials of antidepressant treatment. This review examines the issues fundamental to the systematic evaluation of antidepressant treatment adequacy and resistance. These issues include the domains of interventions deemed effective in treatment of major depressive episodes (e.g., pharmacotherapy, brain stimulation, and psychotherapy), the subgroups of patients for whom distinct adequacy criteria are needed (e.g., bipolar vs. unipolar depression, psychotic vs. nonpsychotic depression), whether trials should be rated dichotomously as adequate or inadequate or on a potency continuum, whether combination and augmentation strategies require specific consideration, and the criteria used to evaluate the adequacy of treatment delivery (e.g., dose, duration), trial adherence, and clinical outcome. This review also presents the Antidepressant Treatment History Form: Short-Form (ATHF-SF), a completely revised version of an earlier instrument, and details how these fundamental issues were addressed in the ATHF-SF.HumansAntidepressive AgentsTreatment OutcomeDeep Brain StimulationPsychotherapyDepressive Disorder, Treatment-ResistantSurveys and QuestionnairesJournal article2022-04-13